Shu Wang

Academic / Other · 8 registered clinical trials — 8 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients HER2-positive Breast Cancer	—	2019-01-01
Recruiting	Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherap HER2-positive Breast Cancer	—	2019-01-01
Recruiting	Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast C HER2-positive Breast Cancer	—	2019-01-01
Recruiting	Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC Triple Negative Breast Cancer	—	2019-01-01
Recruiting	Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy HER2-positive Breast Cancer	—	2019-01-01
Recruiting	Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer HER2-positive Breast Cancer	—	2019-01-01
Recruiting	De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients HER2-positive Breast Cancer	—	2015-01-01
Recruiting	Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer HER2-positive Breast Cancer	—	2015-01-01